findmyKOL

Angela Demichele, MD

Basic profile

Mariann T. and Robert J. MacDonald Professor in Breast Cancer Care Excellence; Director of Clinical/Translational Research in Solid Oncology · University of Pennsylvania

ORCID↗NPI↗
✓ Full record
Region🇺🇸 Philadelphia, PA · Northeast · United StatesSpecialtyMedical OncologyFocusBreast Cancer Treatment Studies+4
Active KOLfindmyKOL type: EliteLatest publicationSee ScholarshipOnline presenceverified 2026Payments2021 onwardNIH funding1999–2026Why? →

Angela Demichele is Mariann T. and Robert J. MacDonald Professor in Breast Cancer Care Excellence; Director of Clinical/Translational Research in Solid Oncology at University of Pennsylvania. OpenAlex indexes 739 publications with 29,081 citations (h-index 90); ClinicalTrials.gov lists 7 registered studies matched to this name.

Overview

Updated 16 Oct 2026

Angela Demichele, MD, is Mariann T. and Robert J. MacDonald Professor in Breast Cancer Care Excellence at University of Pennsylvania, Perelman School of Medicine, Abramson Cancer Center. The public record shows 763 publications with 28,897 citations (h-index 90), centered on Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, PARP inhibition in cancer therapy. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 2 companies, 4 NIH-funded awards (1999–2026).

  • Most recent indexed publication: 2026 · Journal of clinical oncology
  • Top research focus: Breast Cancer Treatment Studies
  • 13 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 2 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Breast Cancer13 trialsNeoplasm, Residual1 trial

Research focus

OpenAlex concept fingerprint
Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesPARP inhibition in cancer therapyBRCA gene mutations in cancerCancer survivorship and care

Drugs & molecules

across trials, industry payments and publications
Ibrancegeneric · PalbociclibClinical trials—Industry payments2Publications13

Works with

trial sponsors and companies reporting payments
Abramson Cancer Center at Penn MedicineClinical trials10Industry payments—Pfizer Inc.Clinical trials—Industry payments3Alliance Foundation Trials, LLC.Clinical trials1Industry payments—Dana-Farber Cancer InstituteClinical trials1Industry payments—Gilead Sciences, Inc.Clinical trials—Industry payments1University of PennsylvaniaClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
739publications

Distinct works indexed by OpenAlex, matched via ORCID.

29,081citations

Total citations across indexed works.

90h-index

Hirsch index (OpenAlex). i10-index 267.

Clinical & industry

trials, payments and federal funding
7clinical trials

Investigator role on registered studies.

View trials ↓
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
4NIH grants · 1999–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

3400 Spruce St.
14 Penn Tower
Philadelphia, PA 19104

Telephone

215-349-5730

Registry record last updated 12 Sept 2019 · collected 28 Jul 2026.

View the NPPES registry record

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:

All 7 trial records: search, sort and filter.Explore →

Industry payments

Updated 16 Oct 2026

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Aromatase Inhibitor54.8%
    Anastrozole100%
    Part D<11 patients
    Kinase inhibitor45.2%
    Ibrance100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 16 Oct 2026

4 NIH research awards on record, funded 1999–2026 per NIH RePORTER. The latest:

All 43 award records: search, sort and filter.Explore →

Congress activity

Updated 16 Oct 2026

218 congress contributions (2004–2026) across AACR, ASCO, ESMO, SABCS per OpenAlex. The most recent:

All 218 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 5 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
    Article1,815 citations2016
    doi.org ↗
  2. 02
    Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
    Article1,268 citations2018
    doi.org ↗
  3. 03
    Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
    Article707 citations2020
    doi.org ↗
  4. 04
    Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
    Article585 citations2017
    doi.org ↗
  5. 05
    Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
    Article554 citations2016
    doi.org ↗
All 739 cited works: search, sort and filter.Explore →

Network

Updated 16 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Laura J. Esserman193Hope S. Rugo161Christina S. F. Yau154Amy Sanders Clark146W. Fraser Symmans134Douglas Yee133Jane Perlmutter102Nola M. Hylton99Gillian L. Hirst97Laura van ‘t Veer94Denise M. Wolf93Lamorna Brown Swigart93Rita Nanda87Claudine J. Isaacs85Donald A. Berry84Kevin R. Fox69Judy Caroline Boughey66Kathy S. Albain64Susan M. Domchek64Amy Jo Chien63Peter James O'Dwyer62Erica Michelle Stringer-Reasor61ANTHONY D. ELIAS59Lajos Pusztai58Michael D. Feldman58Smita M. Asare57Paul J. Zhang57MC Liu57Anne Marie Wallace55EL Mayer54Mark Alan Rosen54Kathy D. Miller49Antonio C. Wolff47Debu Tripathy47Jun J. J. Mao45Sibylle Loibl45Meredith Buxton44Ashish P. Sanil44Rosemarie Mick42Massimo Cristofanilli41

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/angela-demichele-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

Mentions by others

where others cite or feature them
  • Other

    reachmd.com/profiles/angela-demichele-md-msce/LdgGv6/biography

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →reachmd.com ↗
  • Other

    breastcancer.org/bio/angela-demichele

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →breastcancer.org ↗
  • Other

    lbbc.org/about-us/medical-advisory-board/angela-demichele-md-msce

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lbbc.org ↗
  • Other

    pennmedicine.org/providers/profile/angela-demichele

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • M.S.C.E. in Clinical Epidemiology

    University of Pennsylvania

    2001
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
  • M.D.

    Washington University School of Medicine

    1991
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
  • B.A. in Biochemistry

    Brown University

    1988
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗

Editorial & leadership roles

journal and society appointments
  • Co-Director

    2-PREVENT Breast Cancer Translational Center of Excellence

    2013
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
  • Co-Chair

    ECOG/ACRIN Cooperative Group Breast Committee

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
  • Chair

    Trial Operations Working Group, I-SPY Consortium

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
  • Member

    NCI Breast Cancer Steering Committee

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
  • Chair-elect

    ASCO Scientific Program Committee

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
  • Candidate for ASCO Board of Directors
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗

Awards & honors

honors on the public record

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”